U.S. flag An official website of the United States government
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention
  1. Regulatory Information

GUIDANCE DOCUMENT

Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention March 2008

Draft

Not for implementation. Contains non-binding recommendations.

Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention

Issued by:
Guidance Issuing Office
Center for Drug Evaluation and Research

This guidance provides recommendations for the development of drugs and therapeutic biologics regulated within the Center for Drug Evaluation and Research at the Food and Drug Administration (FDA) for the treatment and prevention of diabetes mellitus. The intention of this guidance is to serve as a focus for continued discussions among the review divisions, pharmaceutical sponsors, academic community, and the public. The organization of the guidance parallels the development plan for a particular drug or biologic. In the following discussion, we briefly describe type 1 and type 2 diabetes mellitus and treatment goals, discuss issues relevant to preclinical development, and then provide guidance on issues related to trial design, endpoints appropriate for different phases of development, and eligible populations. These issues are addressed for both type 1 and type 2 diabetes mellitus.


Submit Comments

Submit comments on this guidance document electronically via docket ID: FDA-2013-S-0610 - Specific Electronic Submissions Intended For FDA's Dockets Management Staff (i.e., Citizen Petitions, Draft Proposed Guidance Documents, Variances, and other administrative record submissions)

If unable to submit comments online, please mail written comments to:

Division of Dockets Management (HFA- 305)
Food and Drug Administration
5630 Fishers Lane, Rm. 1061
Rockville, MD 20852

All comments should be identified with the title of the guidance.